TISIDB

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00291 Pyridoxal-phosphate dependent enzyme
Function	Catalyzes the synthesis of D-serine from L-serine. D-serine is a key coagonist with glutamate at NMDA receptors. Has dehydratase activity towards both L-serine and D-serine.

> Gene Ontology [ TOP ]
Biological Process	GO:0002237 response to molecule of bacterial origin GO:0006090 pyruvate metabolic process GO:0006520 cellular amino acid metabolic process GO:0006563 L-serine metabolic process GO:0007568 aging GO:0009069 serine family amino acid metabolic process GO:0009070 serine family amino acid biosynthetic process GO:0014072 response to isoquinoline alkaloid GO:0016053 organic acid biosynthetic process GO:0032496 response to lipopolysaccharide GO:0042493 response to drug GO:0042866 pyruvate biosynthetic process GO:0043278 response to morphine GO:0043279 response to alkaloid GO:0044283 small molecule biosynthetic process GO:0046394 carboxylic acid biosynthetic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0070178 D-serine metabolic process GO:0070179 D-serine biosynthetic process GO:0072330 monocarboxylic acid biosynthetic process GO:1901605 alpha-amino acid metabolic process GO:1901607 alpha-amino acid biosynthetic process
Molecular Function	GO:0000287 magnesium ion binding GO:0003941 L-serine ammonia-lyase activity GO:0008721 D-serine ammonia-lyase activity GO:0016594 glycine binding GO:0016597 amino acid binding GO:0016829 lyase activity GO:0016840 carbon-nitrogen lyase activity GO:0016841 ammonia-lyase activity GO:0016853 isomerase activity GO:0016854 racemase and epimerase activity GO:0016855 racemase and epimerase activity, acting on amino acids and derivatives GO:0018114 threonine racemase activity GO:0030165 PDZ domain binding GO:0030170 pyridoxal phosphate binding GO:0030378 serine racemase activity GO:0031406 carboxylic acid binding GO:0036361 racemase activity, acting on amino acids and derivatives GO:0043168 anion binding GO:0047661 amino-acid racemase activity GO:0048037 cofactor binding
Cellular Component	GO:0043025 neuronal cell body GO:0044297 cell body GO:0045177 apical part of cell

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00260 Glycine, serine and threonine metabolism hsa01100 Metabolic pathways
Reactome	-

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SRR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SRR in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SRR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.122	0.739
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.485	0.675
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.156	0.832
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.42	0.36
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.399	0.818
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.445	0.835
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.635	0.0108
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.478	0.476
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.827	0.26
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.236	0.782
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.713	0.517
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.097	0.228

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SRR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRR. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SRR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SRR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SRR
Name	serine racemase
Aliases	ILV1; D-serine ammonia-lyase; D-serine dehydratase
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SRR collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SRR.

ID	Name	Drug Type	Targets	#Targets
DB00114	Pyridoxal Phosphate	Small Molecule	AADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......	54
DB00133	Serine	Small Molecule	AGXT, CBS, SARS, SDS, SPTLC1, SPTLC2, SRR	7

Browse SRR